

AMENDMENTS TO THE CLAIMS

1. through 20. (Cancelled)

21. (Currently amended) A composition for inducing an immune response in a subject, comprising at least ~~one~~ two purified peptide peptides wherein at least a first peptide comprises comprising at least 10 contiguous amino acids of ~~an~~ the amino acid sequence as set forth as SEQ ID NO: 8 ~~or~~ and at least a second peptide comprises at least 10 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

22. (Cancelled)

23. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least ~~one~~ a first peptide comprises at least 15 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 15 contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

24. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least a first peptide comprises at least 20 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 20 contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

25. (Currently amended) A composition for inducing an immune response comprising at least ~~one~~ two purified peptide peptides wherein at least a first peptide comprises an the amino acid sequence as set forth as SEQ ID NO: 8 ~~or~~ and at least a second peptide comprises the amino acid sequence set forth as SEQ ID NO: 14.

26. (Currently amended) A method of making a composition for inducing an immune response in a mammal comprising combining a pharmaceutically acceptable excipient with at least ~~one~~ two purified ~~peptide peptides having an~~ wherein at least a first peptide comprises the amino acid sequence as set forth as SEQ ID NO: 8 ~~or~~ and at least a second peptide comprises the amino acid sequence set forth as SEQ ID NO: 14.

27. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 21 to a mammal.

28. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 24 to a mammal.

29. (Previously added) The method of claim 26, wherein the mammal is a human.

30. (Previously added) The method of claim 27, wherein the mammal is a human.

31. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 23 to a mammal.

32. (Previously added) The method of claim 31, wherein the mammal is a human.

33. (Previously added) The method of claim 28, wherein the mammal is a human.

34. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 25 to a mammal.

35. (Previously added) The method of claim 34, wherein the mammal is a human.

36. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least ~~one~~ a first peptide comprises at least 25 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 25

contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

37. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 36 to a mammal.

38. (Previously added) The method of claim 37, wherein the mammal is a human.

39. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least ~~one~~ a first peptide comprises at least 30 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 30 contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

40. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 39 to a mammal.

41. (Previously added) The method of claim 40, wherein the mammal is a human.

42. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least ~~one~~ a first peptide comprises at least 40 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 40 contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

43. (Previously added) A method of inducing an immune response in a subject, comprising administering a composition according to claim 42 to a mammal.

44. (Previously added) The method of claim 43, wherein the mammal is a human.

45. (Currently amended) The composition of claim 21 wherein ~~the sequence of the~~ at least ~~one~~ a first peptide comprises at least 45 contiguous amino acids of ~~at least one of the~~ amino acid sequence set forth as SEQ ID NO: 8 and at least a second peptide comprises at least 45 contiguous amino acids of the amino acid specified sequences sequence set forth as SEQ ID NO: 14.

46. (Currently amended) A method of inducing an immune response in a subject, comprising administering a composition according to claim 34 ~~45~~ to a mammal.

47. (Previously added) The method of claim 46, wherein the mammal is a human.

48. (New) A composition for inducing an immune response in a subject, comprising at least one purified peptide comprising at least 10 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

49. (New) A method of inducing an immune response in a subject, comprising administering a composition according to claim 48 to a mammal.

50. (New) The method of claim 49, wherein the mammal is a human.

51. (New) The composition of claim 48 wherein the sequence of the at least one peptide comprises at least 15 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

52. (New) A method of inducing an immune response in a subject, comprising administering a composition according to claim 51 to a mammal.

53. (New) The method of claim 52, wherein the mammal is a human.

54. (New) The composition of claim 48 wherein the sequence of the at least one peptide comprises at least 20 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 14.

55. (New) A method of inducing an immune response in a subject, comprising administering a composition according to claim 54 to a mammal.

56. (New) The method of claim 55, wherein the mammal is a human.

57. (New) A method of making a composition for inducing an immune response in a mammal comprising combining a pharmaceutically acceptable excipient with at least one purified peptide comprising at least 10 contiguous amino acid residues of the amino acid sequence set forth as SEQ ID NO: 14.
